Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, significantly enhancing its immunology drug portfolio with Syfovre and another commercial asset. This move offers developers and tech professionals in biotech a notable example of how large pharmaceutical companies are expanding through strategic acquisitions to integrate advanced treatments into their offerings. Watch for potential shifts in Biogen’s research focus towards more immunological disorders following this acquisition.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





